Market Newsdesk

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of MoneyGram International, Inc. (NASDAQ: MGI) between June 17, 2019 and February 22, 2021, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=moneygram-international-inc&id=2637 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=moneygram-international-inc&id=2637

If you wish to serve as lead plaintiff, you must move the Court before the April 30, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- XRP, the cryptocurrency that MoneyGram was utilizing as part of its Ripple partnership, was viewed as an unregistered and therefore unlawful security by the SEC; in the event that the SEC decided to enforce the securities laws against Ripple, MoneyGram would be likely to lose the lucrative stream of market development fees that was critical to its financial results throughout the Class Period; and as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

Miami, Florida, March 31, 2021 (GLOBE NEWSWIRE) — Blue Star Foods Corp. (OTC:BSFC) (“Blue Star” or the “Company”), a sustainable seafood company, announced today that three new directors were appointed to its board of directors, effective as of April 12^th, 2021.

The new board members include Mr. Jeffrey Guzy, Mr. Tim McLellan and Mr. Trond Ringstad, who will be joining existing board members, Mr. Nubar Herian, and Chairman & CEO, Mr. John Keeler.

“We believe these three individuals will significantly strengthen our board with their decades of relevant experience. Certain of the members, like Jeff Guzy, will add publicly traded company experience, while Tim McLellan and Trond Ringstad have vast seafood industry expertise, including in supply-chain logistics, category management and merchandising,” said John Keeler, CEO of Blue Star. “They will provide valuable strategic guidance as we continue to pursue new acquisition opportunities in both the established seafood industry and as we enter the emerging Recirculatory Aquaculture Systems (RAS) space.”

Mr. Keeler continued, “Importantly, their appointment as directors help us meet several key initial requirements for listing on a senior national exchange, including having five directors on the board, of which the majority are independent, and several of whom also meet certain sub-committee qualifications.”

The brief corporate biographies of Blue Star’s new directors are:

Jeffrey Guzy | Mr. Guzy has more than 20 years of public company board experience, including currently serving as an independent director and chairman of the audit committee for Leatt Corp. (OTC:LEAT), Capstone Companies, Inc. (OTC:CAPC) and Purebase Corporation (OTC:PUBC). He previously served in executive operating roles at multiple technology and telecommunications companies, including IBM Corporation, Sprint International, Bell Atlantic Video Services and Loral CyberStar.

Tim McLellan | Mr. McLellan has more than 35 years of operating experience and has served as a seafood executive in both the U.S. and Asia including as the President of Empress International, a division of Thai Union Group (SET:TU) and in a Senior Manager position with the seafood division of ConAgra Foods (NYSE:CAG).

Trond Ringstad | Mr. Ringstad has more than 20 years of operating experience and has served as a seafood executive in both the U.S. and Europe including as President of Pacific Supreme Seafoods, a global importing and wholesaling seafoods company, which he sold to a publicly traded company. He also served as Vice President of Sales and Marketing for Royal Supreme Foods, a Norwegian / Chinese seafood importer and sales company.

About Blue Star Foods Corp.

Blue Star is a sustainable seafood company that processes, packages, and sells refrigerated pasteurized Blue Crab meat, and other premium seafood products. The Company believes it utilizes best-in-class technology, in both resource sustainability management and traceability, and ecological packaging. Its products are currently sold in the United States, Mexico, Canada, the Caribbean, the United Kingdom, France, the Middle East, Singapore, and Hong Kong. The Company’s headquarters are in Miami, Florida (United States), and its corporate website is: http://www.bluestarfoods.com.

Safe Harbor

This press release contains statements, which may constitute “forward-looking statements”. Those statements include statements regarding the intent, belief, or current expectations of the Company and members of its management team, as well as the assumptions on which such statements are based. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that may cause actual results to differ from those anticipated are discussed throughout the Company’s reports filed with Securities and Exchange Commission which are available at www.sec.gov as well as the Company’s web site at http://www.bluestarfoods.com. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contacts

Brett Maas, Managing Partner, Hayden IR
(646) 536-7331, [email protected]

Constantino Gutierrez | Newbridge Securities Corporation
(480) 207-1824 | [email protected]

ATLANTA, March 31, 2021 (GLOBE NEWSWIRE) — Federal Home Loan Bank of Atlanta (FHLBank Atlanta) today announced the retirement of W. Wesley McMullan as President and CEO, effective May 27, 2021. Kirk Malmberg has been appointed as President and Chief Executive Officer.

McMullan has led the Bank since 2010. Prior to his appointment as President and CEO, he served as Executive Vice President and oversaw asset liability management, member sales and trading, and financial operations management. McMullan joined the Bank as a credit analyst in 1988.

“We are sincerely grateful for Wes’s 33 years of service and dedication to the Bank and to the FHLBank System,” said Rick Whaley, chair of the FHLBank Atlanta board of directors. “The example set by Wes’s long and meaningful career is the epitome of what makes the Bank special, and it underscores the advancement opportunities that are possible at FHLBank Atlanta.”

“Through times of challenge and prosperity, I’m thankful for the opportunity to execute the Bank’s vital mission to contribute to the success of our shareholders,” said McMullan. “It has been the deepest honor to work for FHLBank Atlanta, its shareholders, and the communities they serve.”

As the Bank transitions leadership, Malmberg brings 24 years of experience with the FHLBank System including 19 years at FHLBank Atlanta. He has served in significant leadership roles in the Bank, including as its Chief Financial Officer, Chief Credit Officer, and most recently as the Bank’s Executive Vice President and Chief Operating Officer.

“We are fortunate to have Kirk as our new President and Chief Executive Officer,” said Chair Whaley. “Kirk brings a strong record of accomplishment and depth of knowledge about the Bank and the FHLBank System that will serve our shareholders well.”

“I’m humbled by the opportunity to lead the Bank as President and CEO and work with our staff to help our members serve their communities,” said Malmberg.

Malmberg will assume the role of President and CEO effective May 28, 2021.

About the Federal Home Loan Bank of Atlanta


FHLBank Atlanta offers competitively-priced financing, community development grants, and other banking services to help member financial institutions make affordable home mortgages and provide economic development credit to neighborhoods and communities. The Bank’s members—its shareholders and customers—are commercial banks, credit unions, savings institutions, community development financial institutions, and insurance companies located in Alabama, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, and the District of Columbia. FHLBank Atlanta is one of 11 district banks in the Federal Home Loan Bank System. Since 1990, the FHLBanks have awarded approximately $6.6 billion in Affordable Housing Program funds, assisting more than 957,000 households.

For more information, visit our website at www.fhlbatl.com.

CONTACT: Sharon B. Cook
Federal Home Loan Bank of Atlanta
[email protected]
404.888.8173

Molecular Mirror™ Detection Technology Allows for Screening of More Than 100,000 Patient Specimens Per Day Using Standard MRI Systems Available in Hospitals

San Diego, CA, March 31, 2021 (GLOBE NEWSWIRE) —

via NewMediaWire — Menon Biosensors, Inc. (“Menon” or the “Company”), a subsidiary of Menon International, Inc., a distributive technology portfolio company with assets in ag-tech and diagnostics, announced today that it has qualified for the XPRIZE Alumni Network.

This comes as a result of Menon’s development of an advanced system and method for detecting the SARS-CoV-2 (COVID-19) virus. The system, known as Molecular Mirror™, is a detection technique that produces 100% accurate results within 30 minutes of bacterial and viral pathogens. 

The Alumni Network membership is a prestigious service that identifies Molecular Mirror™ method to be amongst the top-performing assays for detecting COVID. Through this vehicle, the team will stay in touch with supporting organizations that have participated in XPRIZE competitions as they scale their solutions after the competition is over. Benefits include access to valuable resources such as investors, potential partners and customers, business mentors, marketing and exposure, and more.

In addition to the Alumni Network, Molecular Mirror™ team’s contact information was shared with the $50 million COVID Apollo Project led by experienced life sciences investors and company builders that will work with OpenCovidScreen, the XPRIZE community, and beyond to accelerate the best ideas, technologies, and innovations to market and scale them.

“We are pleased to be accepted into the XPRIZE Alumni Network and utilize their extensive resources to bring the Molecular Mirror™ to the masses,” said Dr. Suresh Menon, Founder and President of Menon. “The technology is highly effective and extremely versatile. By leveraging existing hospital MRI equipment, Menon’s COVID-19 screening technology is capable with sample testing rates of greater than 100,000 samples per hour, per site.”

The Molecular Mirror™ assay has achieved 100% detection with no false positives in multiple double-blind tests validated by the U.S. Department of Homeland Security, the U.S. Defense Threat Reduction Agency, and various universities and other private clients. Menon’s rapid, ultra-low Level of Detection (LOD of 3-5 viral copies), sensitive, and specific assay for detection of the COVID-19 virus is based on binding nucleic acids to proprietary magnetic nanoparticles without the need for nucleic acid extraction. Large-scale detection has been demonstrated using existing Magnetic Resonance Imaging (MRI) systems that are common in standard metropolitan hospitals at a cost competitive to assays currently in the market. This test can be performed with any MRI machine in the world.

The Molecular Mirror™ assay achieves high sensitivity and specificity by use of magnetic nanoparticles functionalized with target-specific biomarkers that bind to specific regions of a pathogen’s genome. The sample, with bound nanoparticles, is then processed to produce a change in its magnetic properties, specifically the “spin-spin relaxation time,” thus producing a signal in the presence of the target of interest, in this case detecting the COVID-19 virus.

For more information about Menon, please visit MenonBiosensors.com/.

About Menon Biosensors, Inc.

Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens.  Menon Biosensors’ Molecular Mirror™ NMR-based platform technology (classified by the U.S. Government until 2012) provides superior sensitivity and specificity and minimizes sample preparation, providing best in class sample-to-answer pathogen detection. The technology has been validated by respected Universities and diagnostic companies.

About XPRIZE

XPRIZE is a global future-positive movement of over 1M people and rising, delivering truly radical breakthroughs for the benefit of humanity. XPRIZE inspires and empowers a global community of problem-solvers to positively impact our world by crowdsourcing solutions through large-scale competitions, tackling the world’s grandest challenges in exploration, environment and human equity. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1 Million Digital Learning Challenge. Donate, sign up or join a team at xprize.org.

Press Contact:

Kyle Porter

CMW Media, President

[email protected]

+1 858.264.6600

Corporate Contact:

Menon Biosensors, Inc.

[email protected]

+1 858.675.9990

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Tyson Foods, Inc. (NYSE: TSN) between March 13, 2020 and December 15, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=tyson-foods-inc&id=2581 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=tyson-foods-inc&id=2581

If you wish to serve as lead plaintiff, you must move the Court before the April 5, 2021 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that-     Tyson knew, or should have known, that the highly contagious coronavirus was spreading throughout the globe; Tyson did not in fact have sufficient safety protocols to protect its employees in its facilities; as a result, Tyson employees contracted and spread the coronavirus within the facilities; as a result of the foregoing, Tyson would face negative impact to its production, including complete shutdowns of certain facilities; and due to the failure to protect its employees, Tyson would suffer financial harm related to its lowered production. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=athenex-inc&id=2652  or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=athenex-inc&id=2652

If you wish to serve as lead plaintiff, you must move the Court before the May 3, 2021 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- the data included in the Oral Paclitaxel and Encequidar New Drug Application (“NDA”) presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; the uncertainty over the results of the primary endpoint of objective response rate (“ORR”) at week 19 conducted by blinded independent central review (“BICR”); the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Renewable Energy Group, Inc. (NASDAQ: REGI) between May 3, 2018 and February 25, 2021, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=renewable-energy-group-inc&id=2643 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=renewable-energy-group-inc&id=2643

If you wish to serve as lead plaintiff, you must move the Court before the May 3, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- due to failures in the diesel additive system, petroleum diesel was not periodically added to certain loads by the Company and was instead added by the Company’s customers; as a result, Renewable Energy Group was not the proper claimant for certain biodiesel tax credit (BTC) payments on biodiesel it sold between January 1, 2017 and September 30, 2020; a result, Renewable Energy Group’s revenue and net income were overstated for certain periods; there was a material weakness in the Company’s internal control over financial reporting related to the purchase and use of the petroleum diesel gallons when blending with biodiesel; and that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Ontrak, Inc. (NASDAQ: OTRK) between November 5, 2020 and February 26, 2021, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=ontrak-inc&id=2645 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=ontrak-inc&id=2645

If you wish to serve as lead plaintiff, you must move the Court before the May 3, 2021 DEADLINE.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- Ontrak’s largest customer evaluated the Company on a provider basis, valuing Ontrak’s performance based on achieving the lowest cost per medical visit rather than clinical outcomes or medical cost savings; as a result, Ontrak’s largest customer did not find the Company’s program to be effective and was reasonably likely to terminate its contract with Ontrak; because this customer accounted for a significant portion of the Company’s revenue, the loss of the customer would have an outsized impact on Ontrak’s financial results; and as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Ebix, Inc. (NASDAQ: EBIX) between November 9, 2020 and February 19, 2021, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=ebix-inc&id=2624 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=ebix-inc&id=2624

If you wish to serve as lead plaintiff, you must move the Court before the April 23, 2021 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix’s gift card business in India during the fourth quarter of 2020; there was a material weakness in Company’s internal controls over the gift or prepaid revenue transaction cycle; the Company’s independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel; and as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756